Eledon Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Eledon Pharmaceuticals announces its 2026 Annual Meeting of Stockholders to elect directors, increase authorized shares, and ratify its auditor.
NASDAQ
Eledon Pharmaceuticals is holding its annual stockholder meeting on June 10, 2025, seeking approval for key proposals including increasing authorized common stock and officer exculpation.
NASDAQ
DEF 14A: Eledon Pharmaceuticals Seeks Stockholder Approval for Share Increase and Officer Exculpation
Eledon Pharmaceuticals is asking stockholders to vote on proposals to increase authorized shares and provide liability protection for officers at the upcoming annual meeting.
NASDAQ
Eledon Pharmaceuticals will hold its annual stockholders meeting on July 10, 2024, to elect directors, approve an amendment to the 2020 Incentive Plan, and ratify the appointment of its accounting firm.
NASDAQ
Eledon Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders to elect directors, approve an amendment to the 2020 Long Term Incentive Plan, and ratify the appointment of its independent auditor.